SMMT
Summit Therapeutics Inc.
2.13
USD
This page is just a preview of the data found in TrendSpider’s full version
Summit Therapeutics Inc. stock is up 5.97% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 December’s closed higher than November. In the last 7 Unusual Options Trades, there were 7 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 17 Oct 13:44 | 19 Jan, 2024 | 2.00 | 4991 | ||
| 17 Oct 13:51 | 19 Jan, 2024 | 2.00 | 4991 | ||
| 17 Oct 14:06 | 19 Jan, 2024 | 2.00 | 4991 | ||
| 03 Nov 15:39 | 19 Jan, 2024 | 2.00 | 9240 | ||
| 03 Nov 16:22 | 19 Jan, 2024 | 2.00 | 9240 | ||
| 07 Nov 15:19 | 19 Jan, 2024 | 2.00 | 6590 | ||
| 07 Nov 15:56 | 19 Jan, 2024 | 2.00 | 6590 |
Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.
